BTK and primary central nervous system lymphoma: Tirabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, has recently emerged as an effective treatment option for recurrent or refractory PCNSL [12], with a study reporting the efficacy of tirabrutinib for CNS lymphoma arising in IDD.